The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N02 | Analgesics | |
| 3 | N02C | Antimigraine preparations | |
| 4 | N02CC | Selective serotonin (5HT1) agonists | |
| 5 | N02CC03 | Zolmitriptan |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| NASAL - Nasal | 2.5 mg |
| ORAL - Oral | 2.5 mg |
| Active Ingredient | Description | |
|---|---|---|
| Zolmitriptan |
Zolmitriptan has been demonstrated to be a selective agonist for the vascular human recombinant 5HT1B and 5HT1D receptor subtypes. Zolmitriptan is a high affinity 5HT1B/1D receptor agonist with modest affinity for 5HT1A receptors. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ZOLMITRIPTAN Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| ZOLMITRIPTAN Orodispersible tablets | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| ZOMIG Film-coated tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
| ZOMIG Nasal spray | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
